Cost-Effectiveness Analysis of a Genetic Screening Program in the Close Relatives of Spanish Patients With Familial Hypercholesterolemia

Oliva, Juan; López-Bastida, Julio; Moreno, Santiago; Mata, Pedro; Alonso, Rodrigo

doi:10.1016/s1885-5857(09)71514-2

Cited by 19 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For patients in whom the causative mutation is known, cascade testing of their relatives with DNA analysis is very cost-effective because ≈50% of them inherit the mutation. [182][183][184][185] International studies collectively show that the cost per life-year gained for DNA-based cascade testing and intensive statin therapy averages $5000 to $6800, which compares favorably with other widely accepted screening strategies such as mammography for breast cancer. A recent report on the health, social, and economic advantages of treating FH estimated that high-intensity statin therapy would lead to 10% fewer CAD deaths per 1000 FH patients treated (between 30 and 85 years of age) compared with no treatment.…”

Section: Health Economics Of Detection and Treatment Of Fhmentioning

confidence: 99%

The Agenda for Familial Hypercholesterolemia

Gidding¹,

Champagne²,

Ferranti³

et al. 2015

Circulation

561

353

View full text Add to dashboard Cite

Section: Health Economics Of Detection and Treatment Of Fhmentioning

confidence: 99%

The Agenda for Familial Hypercholesterolemia

Gidding¹,

Champagne²,

Ferranti³

et al. 2015

Circulation

561

353

View full text Add to dashboard Cite

“…One study evaluated the cost-effectiveness of an intervention test for cascade testing of relatives. 57 This is cascade testing based on LIPOchip; however, there are less costly methods of cascade testing of relatives (targeted sequencing) and so this analysis may be of limited use for informing the economic evaluation for this appraisal. A number of supplementary studies discussed provide strong evidence that cascade testing of relatives of index cases with FH is cost-effective.…”

Section: Discussionmentioning

confidence: 99%

“…Discussion of included studies evaluating the cost-effectiveness of Elucigene FH20 and/or LIPOchip One study 57 was identified that met our inclusion criteria and evaluated the cost-effectiveness of one of the intervention tests. This study assessed the cost-effectiveness of LIPOchip in identifying and testing first-degree relatives of index cases identified with FH in a Spanish population.…”

Section: Methods (Inclusion and Exclusion Criteria)mentioning

confidence: 99%

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.

Sharma

Boyers²,

Boachie³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for researc...

show abstract

“…Indeed, DNA testing and cascade testing using mutation information have been recommended in the UK, 100 and have been actively implemented in several other countries. [101][102][103] Multimutation testing methods for familial hyper cholesterolemia have been developed, with between 20 and >200 different mutations examined simultaneously. These methods identify mutations in 50-70% of patients.…”

Section: Rare Alleles Of Large Effectmentioning

confidence: 99%

Utility of genetic determinants of lipids and cardiovascular events in assessing risk

et al. 2011

View full text Add to dashboard Cite

The prevention of coronary heart disease (CHD) is a major public-health goal, but disease architecture is such that a larger proportion of clinical events occur among the average majority than among the high-risk minority--the prevention paradox. Genetic findings over the past few years have resulted in the reopening of the old debate on whether an individualized or a population-based approach to prevention is preferable. Genetic testing is an attractive tool for CHD risk prediction because it is a low-cost, high-fidelity technology with multiplex capability. Moreover, by contrast with nongenetic markers, genotype is invariant and determined from conception, which eliminates biological variability and makes prediction from early life possible. Mindful of the prevention paradox, this Review examines the potential applications and challenges of using genetic information for predicting CHD, focusing on lipid risk factors and drawing on experience in the evaluation of nongenetic risk factors as screening tests for CHD. Many of the issues we discuss hold true for any late-onset common disease with modifiable risk factors and proven preventative strategies.

show abstract

Cost-Effectiveness Analysis of a Genetic Screening Program in the Close Relatives of Spanish Patients With Familial Hypercholesterolemia

Cited by 19 publications

References 22 publications

The Agenda for Familial Hypercholesterolemia

The Agenda for Familial Hypercholesterolemia

Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.

Utility of genetic determinants of lipids and cardiovascular events in assessing risk

Contact Info

Product

Resources

About